Hideho Okada

This study identifies Gpr149 as an endogenous antigen in SB28 glioblastoma that can be targeted by vaccination to induce protective immunity against checkpoint inhibitor-refractory tumors.

This study shows that ultrasound-mediated BBB modulation alone does not generate effective CNS immunity, but combining it with systemic immune activation enhances T-cell responses and improves immunotherapy efficacy.

This study identifies ITPKB as a regulator of NK cell desensitization, showing its inhibition enhances antitumor immunity in murine and human models.

This study shows that viral vector vaccination induces brain-resident memory T cells that effectively combat glioblastoma, offering a potential therapeutic strategy.

This paper develops a spike-in probe-enhanced scRNA-seq method to track and profile synNotch-CAR-T cells in vivo, revealing tissue-specific activation and transcriptional states.

This study analyzes multi-omic data from gliomas to identify therapeutic escape mechanisms and TME evolution, finding that N-glycosylation classifies tumor grade and immune transcriptome predicts GBM survival.

This study demonstrates closed-loop sonothermogenetic control of CAR T cells to achieve metronomic activation in brain tumors without harming healthy tissue.

This study shows that delivering IRF8 via retroviral vector reprograms myeloid cells in glioblastoma, enhancing anti-tumor immunity and reducing immunosuppression.

This paper develops a PET imaging system using engineered T cells that report antigen recognition through inducible reporter gene expression, showing enhanced signal in antigen-expressing tumors.